Lupin

Lupin Net Debt

The Net Debt of Lupin (LUPIN.NS) as of Nov 3, 2026 is 12.46 B INR. In the previous year, Net Debt was 7.43 B INR — a change of 67.69% (higher).

Net Debt

12.46 BINR

YoY

67.69%

Last updated:

Net Debt of Lupin is 2025 12.46 B INR. Net Debt of Lupin was 2024 7.43 B INR. It decreases by 67.69% higher compared to the previous year.

The Lupin Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
54.41 B INR
Jan 1, 2019
53.66 B INR
Jan 1, 2020
17.36 B INR
Jan 1, 2021
10.18 B INR
Jan 1, 2022
20.54 B INR
Jan 1, 2023
25.89 B INR
Jan 1, 2024
7.43 B INR
Jan 1, 2025
12.46 B INR
The Lupin Net Debt history
YEARNet DebtYoY
12.46 BINR+67.69%
7.43 BINR-71.30%
25.89 BINR+26.06%
20.54 BINR+101.88%
10.18 BINR-41.39%
17.36 BINR-67.64%
53.66 BINR-1.39%
54.41 BINR+5.83%
51.42 BINR-19.17%
63.61 BINR-497.53%
-16.00 BINR+4,791.90%
-327.10 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

Net Debt of Lupin is 12.46 B INR in 2025.

Net Debt of Lupin changed from 7.43 B INR to 12.46 B INR, representing a 67.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Lupin since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Lupin historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lupin

All Key Metrics — Lupin